Elahe Mostaghel

Author PubWeight™ 13.81^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.	JAMA	2006	3.32
2	A molecular correlate to the Gleason grading system for prostate adenocarcinoma.	Proc Natl Acad Sci U S A	2006	2.89
3	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.	J Clin Oncol	2011	1.77
4	Genomic strategy for targeting therapy in castration-resistant prostate cancer.	J Clin Oncol	2009	1.75
5	Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.	J Clin Endocrinol Metab	2013	0.93
6	PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.	Mol Cancer Res	2013	0.92
7	A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.	PLoS One	2013	0.86
8	Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants.	Int J Prev Med	2012	0.79
9	Intraprostatic steroidogenic enzymes - letter.	Cancer Res	2010	0.78